C(-260)T polymorphism in the promoter of CD 14 gene is not associated with myocardial infarction in the Tunisian population

Experimental and Molecular Pathology

Volumn 90, Issue 3, 2011, Pages 276-279

  Sediri, Yousra ^a   Hammami, Sabrine ^a   Kallel, Amani ^a   Mourali, Mohamed Sami ^b   Feki, Moncef ^a   Elasmi, Monia ^a   Haj Taieb, Sameh ^a   Omar, Souheil ^a   Sanhaji, Haïfa ^a   Mechmeche, Rachid ^b   Jemaa, Riadh ^a   Kaabachi, Naziha ^a  

^a Research Laboratory LR99ES11   (Tunisia)

^b LA RABTA HOSPITAL   (Tunisia)

Author keywords

Coronary artery disease; Myocardial infarction; Polymorphism

Indexed keywords

CD14 ANTIGEN;

ADULT; ALLELE; ARTICLE; CD14 RECEPTOR GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HEART INFARCTION; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUNISIA;

ANTIGENS, CD14; CASE-CONTROL STUDIES; DNA, NEOPLASM; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS; TUNISIA;

EID: 79952708594     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.02.004     Document Type: Article

References (19)

1. Elghannam H., Tavackoli S., Ferlic L., et al. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J. Mol. Med. 2000, 78:562-568.
2. Eng H.L., Chen C.H., Kuo C.C., Wu J.S., Wang C.H., Lin T.M. Association of CD14 gene promoter polymorphism and Chlamydia pneumoniae infection. J. Infect. Dis. 2003, 188:90-96.
3. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
4. Hohda S., Kimura A., Sasaoka T., Hayashi T., Ueda K., Yasunami M., Okabe M., Fukuta N., Kurosawa T., Izumi T. Association study of CD14 polymorphism with myocardial infarction in a Japanese population. Jpn Heart J. 2003, 44:613-622.
5. Hubaceck J.A., Rothe G., Pit'ha J., Skodova Z., Stanek V., Poledne R., Schmitz G. C(-260)-T polymorphism in the promotor of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999, 99:3218-3220.
6. Ito D., Murata M., Tanahashi N., Sato H., Sonoda A., Saito I., Watanabe K., Fukvuchi Y. Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. Stroke 2003, 31:2661-2664.
7. Koch W., Kastrati A., Mechilli J., Von Beckerath N., Schoming A. CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction. Am. Heart J. 2002, 143/97166.
8. Koenig W., Khuseyinova N., Hoffman M.M., März W., Fröhlich M., Hoffmeister A., Brenner H., Rothenbacher D. CD14 C(-260)-T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infection and risk of stable coronary artery disease. J. Am. Coll. Cardiol. 2002, 40:34-42.
9. LeVan T.D., Bloom J.W., Bailey T.J., Karp C.L., Halonen M., Martinez F.D., Vercelli D. A common single nucleotide polymorphism in the CD14 promotor decreases the affinity of Sp protein binding and enhances transcriptional activity. J. Immunol. 2001, 167:5838-5844.
10. Liao W. Endotoxin: possible roles in initiation and development of atherosclerosis. J. Lab. Clin. Med. 1996, 128:452-460.
11. Marcadet A., O'Connel P., Cohen D. Standardized Southern blot workshop techniques. Histocompatibility Testing 1987, 587-590. Springer, New York. B. Dupont (Ed.).
12. Mattila K.J., Valtonen V.V., Nieminen M.S., Asikainen S. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin. Infect. Dis. 1998, 26:719-734.
13. Nauck M., Winkelmann B.R., Hoffmann M.M., Böhm B.O., Wieland H., März W. C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am. J. Cardiol. 2002, 90:1249-1252.
14. Shimada K., Watanabe Y., Mokuno H., Iwama Y., Daida H., Yamaguchi H. Common polymorphism in the promoter of the CD14 monocyte receptor gene is associated with acute myocardial infarction in Japanese men. Am. J. Cardiol. 2000, 86:682-684.
15. Unkelbach K., Gardemann A., Kostrzewa, Phillip M., Tillmanns H., Haberbosch W. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction with low atherosclerosis risk profile. Artherioscler Thromb. Vasc. Biol. 1999, 19:932-938.
16. Valtonen V.V. Infection as a risk for infarction and atherosclerosis. Ann. Med. 1991, 23:539-543.
17. World Health Organisation Physical Status: The Use and Interpretation of Anthropometry: Report of a WHO Expert Committee. WHO Technical Report Series no. 854 1995, 321-344. WHO, Genova.
18. Yamada Y., Izawa H., Ichihara S., et al. Prediction of the risk of myocardial infarction from polymorphism in candidate genes. N. Engl. J. Med. 2002, 347:1916-1923.
19. Zee R.Y.L., Lindpaintner K., Struk B., Hennekens C.H., Ridker P.M. A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. Atherosclerosis 2001, 154:699-702.